(PharmaNewsWire.Com, November 03, 2017 ) Market Research Hub (MRH) has included a new research report titled “Huntingtin (Huntington Disease Protein or HTT) Pipeline Review H2 2017”, outlays complete info on the Huntingtin or Huntington Disease Protein or HTT targeted therapeutics, whole with the strong analysis by indications, route of administration (RoA), mechanism of action (MoA), stage of development and molecule type; that are being established by Companies / Universities.
According to the recently published report Huntingtin-Pipeline Review, H2 2017; Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Huntingtin (Huntington Disease Protein or HTT)-Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD (Huntington disease) gene. Huntingtin up regulates the expression of brain derived neurotrophic factor (BDNF) at the transcription level. Huntingtin is primarily associated with vesicles and microtubules. These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A.
It also reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, the molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Huntington Disease, Alzheimers Disease, Kennedys Disease (Spinal and Bulbar Muscular Atrophy) and Spinocerebellar Ataxia (SCA).
Scope: - The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein or HTT) - The report reviews Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics and enlists all their major and minor projects - The report assesses Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics
Reasons to buy: - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein or HTT) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein or HTT) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Content: List of Tables List of Figures Introduction Global Markets Direct Report Coverage Huntingtin (Huntington Disease Protein or HTT)-Overview Huntingtin (Huntington Disease Protein or HTT)-Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Huntingtin (Huntington Disease Protein or HTT)-Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Huntingtin (Huntington Disease Protein or HTT)-Companies Involved in Therapeutics Development AFFiRiS AG Ionis Pharmaceuticals Inc Neurimmune Holding AG nLife Therapeutics SL PTC Therapeutics Inc reMYND NV Shire Plc
About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients and customers.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: